New strategy for COVID-19 vaccination: targeting the receptor

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3

New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein

News & Comment Cellular & Molecular Immunology

PDF) Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2

Junzhi Wang's research works National Institutes for Food and Drug Control, China, Beijing (NIFDC) and other places

PDF) New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein

COVID-19 vaccine - Wikipedia

Broadly neutralizing antibody could fight new COVID-19 variants

COVID-19 vaccine - Wikipedia

Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein - ScienceDirect

Frontiers COVID-19 Vaccination in Pregnancy and Lactation